Skip to main content
. Author manuscript; available in PMC: 2011 Jun 13.
Published in final edited form as: Bioorg Med Chem Lett. 2010 Mar 7;20(8):2448–2451. doi: 10.1016/j.bmcl.2010.03.020

Table 1.

Percentage of the major oxaliplatin–DNA adducts obtained from HPLC–AMS data (Fig. 3), which summarizes the percentages of the radiocarbon-labeled oxaliplatin–DNA adducts from the HPLC fractions, to determine the cell-dependence manner of the individual adduct concentration (compositional pattern)

MDA-MB-231 833K T24
Monoadducts 6.22 ± 1.43 8.10 ± 1.40 10.6
Pt-1,2-d(GpG) 3.79 ± 1.23 7.54 ± 1.19 3.63
Pt-1,2-d(GpA) or Pt-1,2-d(ApG) 3.12 ± 1.30 0.969 ± 0.59 0.977
Pt-1,3-d(GpNpG) or Pt-(dG)2 3.83 ± 1.59 10.7 ± 1.53 8.89
Pt-(dA)2 4.35 ± 1.42 11.1 ± 1.38 17.4
Not determined ~76.9 ~59.5 54.9
Σ 98.2 97.9 96.4

Σ represents the percentage summation of the major oxaliplatin–DNA adducts listed and not determined row, compared to the total radiocarbon content in cellular DNA. The data for T24 cells were from our previously published paper (Ref. 6).